Abstract
Treatment of chronic hepatitis B has shown a rapid development in the last years leading to a shift of treatment strategies from interferon to hepatitis B virus (HBV)-polymerase inhibitors. In particular, treatment with HBV-polymerase inhibitors has changed the indication on how to treat a patient and when to stop therapy. Long-term treatment with HBV-polymerase inhibitors may often be required, even if it raises the possibility of resistance and subsequent treatment failure. This review provides a strategy on how to manage HBV therapy with the currently available treatment options.
MeSH terms
-
Antiviral Agents / therapeutic use*
-
Drug Resistance, Viral*
-
Drug Therapy, Combination
-
Gene Products, pol / antagonists & inhibitors
-
HIV Infections / drug therapy
-
Hepatitis B e Antigens / immunology
-
Hepatitis B virus / drug effects
-
Hepatitis B virus / physiology
-
Hepatitis B, Chronic / drug therapy*
-
Hepatitis B, Chronic / immunology
-
Hepatitis B, Chronic / virology
-
Humans
-
Interferons / therapeutic use
-
Lamivudine / therapeutic use
-
Virus Replication
Substances
-
Antiviral Agents
-
Gene Products, pol
-
Hepatitis B e Antigens
-
P protein, Hepatitis B virus
-
Lamivudine
-
Interferons